A patient with no underlying hematologic or iron metabolic disorder developed iron induced hepatic cirrhosis as a consequence of long term medicinal iron ingestion. Marked improvement in liver histology followed removal of 28 grams of iron by phlebotomy. Radioautographic studies in rats showed a periportal hepatocyte concentration of radioiron absorbed from the intestine while plasma transferrin was saturated. Based on these and other observations an hypothesis is proposed to explain liver damage in disorders of iron overload.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2279425PMC

Publication Analysis

Top Keywords

hepatic cirrhosis
8
iron
5
medicinal iron-induced
4
iron-induced hepatic
4
cirrhosis reversal
4
reversal phlebotomy
4
phlebotomy studies
4
studies pathogenesis
4
pathogenesis patient
4
patient underlying
4

Similar Publications

Background: Cell therapy demonstrates promising potential as a substitute therapeutic approach for liver cirrhosis. We have developed a strategy to effectively expand murine and human hepatocyte-derived liver progenitor-like cells (HepLPCs) in vitro. The primary objective of the present study was to apply HepLPCs to the treatment of liver cirrhosis and to elucidate the underlying mechanisms responsible for their therapeutic efficacy.

View Article and Find Full Text PDF

Background: Hepatitis B is a liver infection caused by HBV. Infected individuals who fail to control the viral infection develop chronic hepatitis B and are at risk of developing life-threatening liver diseases, such as cirrhosis or liver cancer. Dendritic cells (DCs) play important roles in the immune response against HBV but are functionally impaired in patients with chronic hepatitis B.

View Article and Find Full Text PDF

Goals: To explore dynamic contrast-enhanced ultrasound (CEUS) parameters in predicting hepatic vein pressure gradient (HVPG) for patients with liver cirrhosis (LC).

Background: Noninvasive diagnosis of HVPG remains a challenge.

Study: This prospective study included patients with LC undergoing hepatic vein catheterization and pressure measurement at the hospital from May 2021 to January 2023.

View Article and Find Full Text PDF

Background And Aims: Acute-on-chronic liver failure (ACLF) has a 22%-74% 28-day mortality rate and 30%-40% 30-day readmission rate. We investigated the acceptability and feasibility of a multimodal community intervention for ACLF.

Methods: A single-arm nonrandomized pilot study of consecutive participants with ACLF was conducted in a tertiary health service.

View Article and Find Full Text PDF

Exploring the therapeutic potential of glucagon-like peptide 1 agonists in metabolic disorders.

World J Gastroenterol

January 2025

School of Health Sciences, Universidad Internacional de La Rioja, Logroño 26006, La Rioja, Spain.

This article comments on the work by Soresi and Giannitrapani. The authors have stated that one of the most novel and promising treatments for metabolic dysfunction-associated steatotic liver disease (MASLD) is the use of glucagon-like peptide 1 receptor agonists, especially when used in combination therapy. However, despite their notable efficacy, these drugs were not initially designed to target MASLD directly.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!